[HTML][HTML] Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni… - BMC cancer, 2008 - Springer
Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni… - BMC Cancer …, 2008 - inis.iaea.org
[en] The main objective of this study was to evaluate the safety of second-line pemetrexed in
Stage IIIB or IV NSCLC. Overall, 95 patients received pemetrexed 500 mg/m 2 iv over Day 1 …
Stage IIIB or IV NSCLC. Overall, 95 patients received pemetrexed 500 mg/m 2 iv over Day 1 …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
F Russo, A Bearz, G Pampaloni - BMC Cancer, 2008 - europepmc.org
Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
[HTML][HTML] Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni - BMC Cancer, 2008 - bmccancer.biomedcentral.com
The main objective of this study was to evaluate the safety of second-line pemetrexed in
Stage IIIB or IV NSCLC. Overall, 95 patients received pemetrexed 500 mg/m2 iv over Day 1 …
Stage IIIB or IV NSCLC. Overall, 95 patients received pemetrexed 500 mg/m2 iv over Day 1 …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni… - BMC Cancer (Online …, 2008 - osti.gov
The main objective of this study was to evaluate the safety of second-line pemetrexed in
Stage IIIB or IV NSCLC. Overall, 95 patients received pemetrexed 500 mg/m {sup 2} iv over …
Stage IIIB or IV NSCLC. Overall, 95 patients received pemetrexed 500 mg/m {sup 2} iv over …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni, U Tirelli… - BMC …, 2008 - usiena-air.unisi.it
BACKGROUND: The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. METHODS: Overall, 95 patients received …
pemetrexed in Stage IIIB or IV NSCLC. METHODS: Overall, 95 patients received …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni… - BMC …, 2008 - pubmed.ncbi.nlm.nih.gov
Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
F Russo, A Bearz, G Pampaloni - BMC Cancer, 2008 - search.ebscohost.com
Background: The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods: Overall, 95 patients received pemetrexed …
pemetrexed in Stage IIIB or IV NSCLC. Methods: Overall, 95 patients received pemetrexed …
[引用][C] Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
F Russo, A Bearz, G Pampaloni, N Gebbia - BMC CANCER, 2008 - iris.unipa.it
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or
metastatic non-small cell lung cancer. IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
metastatic non-small cell lung cancer. IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
[HTML][HTML] Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
F Russo, A Bearz, G Pampaloni… - BMC Cancer, 2008 - ncbi.nlm.nih.gov
Background The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …
pemetrexed in Stage IIIB or IV NSCLC. Methods Overall, 95 patients received pemetrexed …